![Howard Davis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Howard Davis
Sociétés | Poste | Début | Fin |
---|---|---|---|
Akamis Bio Ltd.
![]() Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Directeur/Membre du Conseil | 11/08/2022 | - |
Directeur Général | 11/08/2022 | - |
Historique de carrière de Howard Davis
Anciens postes connus de Howard Davis
Sociétés | Poste | Début | Fin |
---|---|---|---|
THIRD HARMONIC BIO, INC. | Directeur des opérations | - | - |
Statistiques
Internationale
Etats-Unis | 2 |
Royaume-Uni | 2 |
Opérationnelle
Chief Operating Officer | 1 |
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
THIRD HARMONIC BIO, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Akamis Bio Ltd.
![]() Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Howard Davis
- Expérience